Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that reduces gastric acid production.
## Primary Indications
* Healing of erosive esophagitis
* Maintenance of healing of erosive esophagitis
* Symptomatic gastroesophageal reflux disease (GERD)
* Pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome)
## Adult Dosing
* **Erosive Esophagitis:** 40 mg orally or intravenously once daily for up to 8 weeks.
* **Maintenance of Healing of Erosive Esophagitis:** 40 mg orally once daily. Some patients may be managed on 20 mg orally once daily.
* **Symptomatic GERD:** 40 mg orally once daily for up to 4 weeks.
* **Pathological Hypersecretory Conditions:** 40 mg orally or intravenously twice daily, may be increased to 80 mg orally or intravenously twice daily.
## Pediatric Dosing
* **Erosive Esophagitis (12 to 16 years):** 40 mg orally once daily for up to 8 weeks.
* **Symptomatic GERD (5 to 16 years):** 20 mg to 40 mg orally once daily for up to 8 weeks.
* **Erosive Esophagitis (1 to <12 years):** Dosing varies by weight.
* 15 kg to <40 kg: 20 mg orally once daily for up to 8 weeks.
* ≥40 kg: 40 mg orally once daily for up to 8 weeks.
* **Symptomatic GERD (1 to <5 years):** Dosing varies by weight.
* <20 kg: 10 mg orally once daily for up to 4 weeks.
* ≥20 kg: 20 mg orally once daily for up to 4 weeks.
## Dose Adjustments
No dose adjustment is generally required for hepatic impairment with oral formulations (maximum daily dose of 40 mg). IV formulation requires dose reduction in moderate to severe hepatic impairment. No dose adjustment is needed for renal impairment.
## Contraindications
Hypersensitivity to pantoprazole or any component of the formulation. Use with rilpivirine is contraindicated.
## Adverse Effects
Common: Headache, diarrhea, nausea, abdominal pain, vomiting, dizziness, flatulence.
## Key Drug Interactions
* **Rilpivirine:** Coadministration is contraindicated due to reduced rilpivirine plasma concentrations.
* **Drugs dependent on gastric pH for absorption:** PPIs may decrease the absorption of drugs such as ketoconazole, itraconazole, nelfinavir, and certain tyrosine kinase inhibitors.
* **Methotrexate:** PPIs may increase methotrexate levels, potentially leading to toxicity.
* **CYP2C19 Substrates (e.g., clopidogrel):** Pantoprazole may inhibit CYP2C19, potentially affecting the efficacy of clopidogrel. Consider avoiding pantoprazole in patients on clopidogrel.
## Monitoring
* Monitor for signs and symptoms of bone fracture, particularly with long-term use.
* Monitor for signs and symptoms of Clostridium difficile-associated diarrhea.
* Monitor serum magnesium levels periodically, especially in patients taking concomitant medications that may lower magnesium levels (e.g., diuretics) or for extended periods (≥1 year).
## Clinical Pearls
* Oral pantoprazole should be taken at least 30 minutes before a meal.
* For IV administration, reconstitute and dilute according to manufacturer instructions. The maximum recommended daily dose for IV administration is 80 mg.
* Long-term PPI use is associated with an increased risk of bone fractures (hip, wrist, spine), Clostridium difficile infection, vitamin B12 deficiency, and hypomagnesemia. Consider the shortest duration of therapy needed to achieve desired clinical outcome.
---
*This information is intended for clinical use and does not substitute for professional medical advice. Always consult current prescribing information and relevant guidelines before making any treatment decisions.*
